- How to strengthen patent portfolios from filing through enforcement
- Navigating the evolving UPC and EPO opposition landscape
- The impact of the EU Pharma Package on exclusivity and lifecycle strategy
- AI in patent prosecution and IP workflow optimisation
- Cross-border litigation strategy and enforcement trends
- Clinical trial transparency and its implications for patent timing
- Building litigation-ready in-house IP functions aligned with business objectives
.png)
Where Life Sciences IP Strategy Comes Full Circle
September 22-23, 2026 | Marriott Basel, Switzerland
View the full topics and speaking faculty here Discover Life Sciences IP News
2 Days | 180 Attendees
Agenda shaped by the needs of pharma and biotech senior executives
.png)
Balanced 1:1 in-house & private practice ratio
Uniting the entire life sciences IP ecosystem under one roof this September! If you want to stay ahead in the rapidly evolving world of pharma and biotech IP, this is where the conversation starts.
Where Life Sciences IP Strategy Comes Full Circle
Life sciences IP is entering a new era, where patent prosecution, litigation strategy, regulatory frameworks, and commercial objectives must operate as one. As the Unified Patent Court (UPC) reshapes enforcement across Europe, AI transforms prosecution workflows, and the EU Pharma Package redefines exclusivity, organisations are under increasing pressure to build resilient, commercially aligned IP strategies.
The opportunities for innovation and growth have never been greater, but success depends on strategic coordination, operational efficiency, and the ability to adapt quickly to a shifting legal and regulatory landscape. From cross-border litigation and SPC reform to biologics disputes and AI-driven drug discovery, the stakes are higher than ever for life sciences innovators.
Join Europe’s leading IP counsel, patent attorneys, litigators, regulators, pharmaceutical and biotech leaders at Life Sciences Patent Network Europe 2026, taking place 22–23 September in Basel, Switzerland — one of Europe’s leading pharmaceutical and biotech hubs.
Over two days, senior decision-makers from organisations including Novartis, Novo Nordisk, BAT, Roche, Leo Pharma, Recordati, SHL Medical, Syngenta, Lonza, and the UPC will come together to explore:
Introducing the 2026 LSPN Europe speaking faculty
Who attends LSPN Europe? Make meaningful connection at our events with the industry decision makers and global legal practitioners:
2026 Confirmed Partners Include:
Coffee Sponsor
Gold Sponsors
Silver Sponsor
Why this is the event for you
End-to-end IP strategy coverage across the full patent lifecycle
Practical, case-led learning grounded in real disputes and landmark decisions
Senior-level networking with Chief IP Counsel, General Counsel, and Heads of IP Strategy & Litigation
Interactive Strategy Circle roundtables delivering peer-to-peer insight and actionable takeaways
Direct access to UPC judges, patent office representatives, and leading practitioners shaping the future of life sciences IP
1:1 ratio of inhouse counsels and private practice to ensure consistent relationship building and knowledge exchange.
LSPN Europe video
Leading companies who register to attend our LSPN events include:
Register your interest today and be the first to receive the 2026 event agenda and full speaking faculty.
SPONSORSHIP:
Ayo Fagbohun
Senior Business Development Manager
WIPR Newton Media
Direct contact
+44 (0) 203 301 8223
REGISTRATION:
Rochelle Clarke
Client Engagement Manager
World IP Review and Life Sciences Review
Direct contact:
+44 203 301 82 43
LSPN Europe 2026 is produced by Newton Media
Contact Us
Newton Media
Kingfisher House
21-23 Elmfield Road
Bromley
BR1 1LT
United Kingdom
Email: info@newtonmedia.co.uk
